In multiple myeloma and melanoma, MCL1 inhibitors like S63845 combined with HDAC inhibitors or redox modulators upregulate pro-apoptotic proteins like BIM and NOXA, resensitizing resistant cells [130,134]. Here, BCL2L11 is linked to plasma cell myeloma.